What is ART-TG ?
The Technological Research Accelerator in Genomic Therapy (ART-TG) was established by Inserm, the french national biomedical institution, to promote excellence in gene therapy research. ART-TG is a center for technological innovation and to advance novel cell and gene therapy concepts towards industrial or clinical phases.
What does ART-TG do ?
ART-TG is a pre-GMP stage R&D laboratory with pharmaceutical expertise. It is expert in ex vivo gene therapy and genome editing technologies. ART-TG develops new therapies, new devices and new processes to produce vectors or gene-modified cells.
What are the domains of interest for ART-TG ?
Two fields in which gene therapy has high innovation potential:
immunotherapy of cancer or of infectious diseases,
treatment of genetic disorders of the blood or of the immune system.
Where is ART-TG located ?
ART-TG is located within the Genopole campus, south of Paris, France.
What is MAGENTA ?
MAGENTA is one of the first industrial integrators that were established in 2020 by the french government to address the challenges of industrial production of biomedicines. MAGENTA was co-founded by ART-TG and by Cithera to foster innovation in cell and gene therapy at the public/private interface.
ART-TG seeks partners looking to innovate in the field of genomic therapy.
Inserm Transfert accompanies the partnerships of ART-TG.